The surface expression of CD79b, using the monoclonal antibody (Mab) CB3-1, on B lymphocytes from normal individuals and patients with B cell chronic lymphocytic leukemia (CLL) has been analyzed using triple-staining cells for flow cytometry. In addition, the clinical significance of CD79b expression in CLL patients and its possible value for the evaluation of minimal residual disease ( + cases, all atypical CLL cases included in the present study were CD79b + and advanced clinical stage (B and C Binet stage) was most frequently observed in CD79b + cases than in CD79b − cases.
Introduction
It has been shown that immunophenotypic analysis is a useful approach for the investigation of minimal residual disease (MRD) in acute leukemia patients. 1 At present this approach has not been used in B cell chronic lymphocytic leukemia (CLL) for MRD detection, with the exception of the kappa/lambda ratio but the sensitivity of this parameter is low (10 −2 ). 1 We and others [2] [3] [4] have explored the incidence of phenotypic aberrances in CLL (maturational asynchronous Correspondence: JA Garcia Vela, Department of Hematology, Hospital Universitario de Getafe, Carretera de Toledo KM 12,500, Getafe 28905, Madrid, Spain; Fax: 34 91 6833541 Received 7 July 1998; accepted 25 May 1999 antigen expression and antigen overexpression) in order to establish the applicability of immunophenotypic aberrances for monitoring MRD as in acute leukemias with a sensitivity level of 10 −4 (one aberrant CLL cell among 10 000 normal cells). We have previously published that CD5 is overexpressed in most CLL cases. 2 This aberrantly CD5 high /CD19
+ expression was present in 90% of our CLL. Dilutional experiments showed that CD5 high /CD19 + were identified at frequencies as low as 10 −4 . Recently, different groups have communicated that CD79b (B cell receptor (BCR), B29 protein) is undetectable in the surface of most CLL cells. 5, 6 This aberrant phenotype (all CD19 + mature lymphocytes express CD79b) has not been studied for monitoring MRD in CLL. The aim of our group was to study the expression of CD79b in CLL, to estimate quantitatively the number of molecules per cell, and finally to explore if this antigen could be used in the detection of MRD by flow cytometry after treatment.
Materials and methods

Patients and samples
A total of 20 healthy donors: 15 peripheral blood (PB) samples and five bone marrow (BM) samples and 40 PB samples from untreated CLL patients were included in the present study. PB and BM aspirates were available for review in all patients, bone marrow trephines in 33 patients and lymph node aspirates or biopsies in 13 cases. All slides were reviewed and classified according to both the REAL classification and the FAB cooperative group criteria. 7, 8 The diagnosis of CLL was confirmed by immunophenotype using a large panel of monoclonal antibodies (Mabs) with a direct immunofluorescence technique: FMC7, CD5, CD10, CD11c, CD19, CD20, CD22, CD23, CD25, CD43, CD103 and polyclonal anti-and antisurface light chains (slg) to determinate B cell clonal excess. A typical CLL immunophenotype was defined as CD5
and slg dim . CLL was further subdivided into typical and atypical CLL on morphology without considering the immunophenotype. 9 Atypical CLL included cases with more than 10% circulating prolymphocytes (CLL/PL) and others with more than 15% lymphocytes with lymphoplasmacytic features and/or cleaved nuclei. According to the REAL classification and FAB criteria, all cases included were classified as CLL. There were no cases with mantle zone lymphoma, follicle center cell lymphoma, lymphoplasmacytoid lymphoma and splenic marginal zone B cell lymphoma. Six out of 40 CLL cases displayed atypical lymphocyte morphology in the blood film.
The mean age of normal blood donors (eight males, seven females) was 49.5 ± 12.9 years and 68.2 ± 11.3 for CLL patients. According to the Binet clinical staging classi-fication, 10 CLL patients were distributed as follows: A 67.5%, B 17.5% and C 15%.
Five patients were studied prior to treatment and at the time of maximal response after fludarabine treatment which was defined as: CR, nodular PR (nPR) or PR. Criteria for CR were normal physical examination, absence of constitutional symptoms, PB lymphocyte count Ͻ4 × 10 9 /l, platelets Ͼ100 × 10 9 /l, Hb Ͼ11 g/dl and Ͻ30% lymphoid cells in the BM aspirate with normal histology. The presence of residual nodular or interstitial lymphoid aggregates in the BM was considered as nPR. The presence of more than 30% lymphocytes in the BM aspirate after normalization of all other parameters was defined as PR.
Five ml of EDTA-anticoagulated PB or BM samples were obtained in all cases after informed consent according to the Hospital Ethical Committee.
Immunophenotypical studies
In all cases unseparated PB samples (1-2 × 10 6 /tube) were stained with a simultaneous triple labeling using the Mabs CD5 and CD22 conjugated with fluorescein isothiocyanate (FITC), CD79b conjugated with phycoerythrin (PE) and CD19 conjugated with the PE/Cyanin5 fluorochrome tandem (Tricolor). Since normal immature BM B cells are CD79b 11 The CD5, CD19, CD22 and CD45 Mabs were purchased from Becton Dickinson (San José, CA, USA), CD79b (CB3-1) from Immunotech (Marseille, France) and CD19-PE/Cy5 from Caltag Laboratories (San Francisco, CA, USA). Samples were incubated for 15 min at room temperature in the dark with saturating amounts of the fluorochrome-conjugated Mab reagents. Afterwards, 2 ml of FACS lysing solution (Becton Dickinson) was added and the samples incubated for 10 min in the same conditions. Then the samples were centrifuged for 15 min at 500 g and the cell pellets washed again with 5 ml of phosphate-buffered saline (PBS). Finally the cells were resuspended in 0.5 ml of PBS for analysis by flow cytometry. An isotype-matched negative control (Becton Dickinson) was used in all cases to assess background fluorescence intensity. Data acquisition was performed on a FACScan flow cytometer (Becton Dickinson) equipped with an argon ion laser tuned at 488 nm and 15 mW. Acquisition was performed in two consecutive steps: in the first step a total of 10 000 events/tube was acquired, and in a second step, cells were acquired through a 'live gate' drawn on the side-scatter (SSC)/CD19 + cells. The total number of nucleated cells acquired depended on the percentage of leukemic cells in the sample. We acquired 10 000, 100 000 and more than 500 000 nucleated cells when the percentages of leukemic cells were 1%, 0.1% and Ͻ0.1%, respectively. In BM samples in the analysis of the 'live gate' SSC/CD19 + we selected those events with CD45 bright intensity. For data analysis, the PAINT-A-GATE PRO software (Becton Dickinson) was used.
Assessment of fluorescence intensity (MESF)
The mean fluorescence intensity was evaluated by the number of molecular equivalents of soluble fluorochrome (MESF), obtained by means of the QUICKCAL beads (Flow Cytometry, San Juan, PR). Each marker was considered to be positive when the mean MESF obtained was at least double that observed in the isotype-negative control tube.
Dilution experiments
Dilution experiments were performed in order to assess the sensitivity level of this technique for the detection of CD79b
+ leukemic cells. For this purpose, progressive dilutions of a CLL sample with normal PB and BM were carried out at ratios of up to one CLL cell in 10 6 normal cells prior to staining with Mabs as previously described.
Statistical analysis
The Mann-Whitney test was used to compare the MESF value of CD79b among the two groups, CLL and normal donors, and to demonstrate the correlation between the expression of CD79b and the other markers analyzed in the present study.
Results
The mean frequency of B lymphocytes CD19
+ in the normal PB samples analyzed was 8.4 ± 4.0% (range: 4.3-14%) of lymphocytes, whereas in CLL PB samples it was 74.09 ± 16.68% (range: 34-98%). The overall proportion of CD19 + cells in the normal BM samples was 3.14 ± 1.68% (range: 0.7-6.4%) and 70.8 ± 14.3% of them showed a bright expression of CD45. In normal PB, B lymphocytes expressing CD5 represented 2.5 ± 1.4% of lymphocytes (MESF 6.6 ± 0.4 × 10 3 ). In the CLL group, all cases were CD5 + and it was expressed in practically all CD19 diluted at frequencies as low as 10 −4 ( Figure 3 ). Dilution experiments with CLL cells with normal CD79b expression were not able to differentiate it from normal B lymphocytes.
We analyzed the expression of CD79b in B lymphocytes from PB and BM in five CLL patients after six courses of fludarabine to support this analysis. Three of five cases were in PR; 1/5 in nPR and 1/5 in CR at the moment of the flow cytometry study. All cases, including the patient considered in CR by bone marrow biopsy, did have leukemic cells (CD19 + with low or undetectable expression of CD79b) detectable by flow cytometry (17.3 ± 7.2% of lymphocytes). With a mean followup of 17 months, all patients relapsed.
Figure 3
Dilution experiments were able to detect one tumoral cell (CD79b negative/CD22 negative/CD19 + ) in 10 4 normal peripheral blood cells (0.01%). Acquisition was performed using a 'live gate' in SSC/CD19
+ cells as described in the text.
Discussion
Surface Ig on B cells is complexed with heterodimers of two critical accessory proteins called B29 (Ig␤ and CD79b) and mb-1 (Ig␣ and CD79a) in the B cell antigen receptor (BCR).
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The presence of perturbation or alterations of either of these genes could prevent surface Ig expression characteristic of CLL cells. 5 In the present study, using a triple-staining procedure and a highly sensitive method for the detection of antigen expression (flow cytometry combined with PE-conjugated monoclonal antibody and a double-step acquisition procedure), we have demonstrated that 92.5% of the CLL samples analyzed in our study had low or negative surface B29 protein that directly correlated with the level of surface Ig expression. Strikingly different results of B29 expression were reported recently in chronic B cell diseases using the SN8 Mab.
6 SN8 was produced by immunizing mice with an antigen preparation from human B-prolymphocytic leukemia cells. It identifies an epitope on the extracellular part of the B29 protein. Because only 5% of their CLL cases had detectable surface expression of B29, they concluded that SN8 could be a useful marker for non-CLL B cell lymphoproliferative disorders. 13 The CB3-1 Mab used by us and Thompson et al 5 also recognizes an extracellular epitope. Its clear specificity for human B29 that can be detected throughout B-lymphocyte differentiation would perhaps make it a more selective antibody for studies of B29 expression. 14 42.5% of our CLL cases were CD79b
− and 50% had a low level of expression of this marker (less than 15 × 10 3 molecules per cell). In contrast mature B lymphocytes from normal blood and BM donors were constantly CD79b
+ with a level of expression higher than 25 × 10 3 molecules per cell. Therefore this marker would appear to be absent or underexpressed in CLL cells, and thus could be considered as a 'tumor phenotype' associated with CLL. In this sense, it would be a useful phenotype for monitoring residual disease in CLL patients. Dilution experiments, in which CD79b
− CLL cells were diluted with normal PB and BM cells, enabled us to detect tumoral cells with a sensitivity level of 10 −4 . Since normal immature BM B cells are CD79b −/dim+ in the analysis of the 'live gate' drawn on the SSC/CD19
+ cells we selected those events with a bright expression of CD45 (mature B lymphocytes with an expression of CD79b identical to PB B lymphocytes). The sensitivity level obtained by flow cytometry to detect residual CLL cells is favorable to the morphology approach (1%) and almost reaches the levels obtained by molecular biology methods, such as the PCR technique. 15 In addition quantitative studies may be useful in samples with a low percentage of CD19 + lymphocytes, and the different intensity of expression of CD79b in normal B lymphocytes and CLL cells can be exploited to identify both populations separately. There have been reports investigating quantitatively the expression of several antigens in CLL 3, 16, 17 but this is the first report investigating quantitatively the expression of CD79b in normal B lymphocytes and CLL cells.
This study demonstrated that flow cytometry contributes to increase the sensitivity of the clinicohematological criteria to detect residual malignant cells in CLL patients and may be useful to monitor disease status and therefore to assess the effectiveness of different therapeutic strategies as allogeneic, autologous bone marrow transplantation or purine analogues. This method may also be useful to evaluate the presence of MRD in the peripheral blood stem cell harvests of CLL patients and to evaluate the different methods of purging. In our patients, we were able to detect leukemic cells after fludarabine treatment, including the case considered in CR. All patients with persistence of MRD assessed by flow cytometry relapsed. Cabezudo et al 3 showed that the persistence of MRD detected by flow cytometry in their patients could be corre- 
/CD19
+ cells was Ͻ0.25 in PB and Ͻ0.15 in BM and the density of expression of both antigens was normal. Recently, we and others 18 have observed an increased number of non-clonal CD5 + B cells in PB of CLL patients after purine analogue therapy ( Figure 4 ). These cells may represent normal B-1a cells and are seen in the PB as the BM regenerates after the chemotherapy. The presence of these cells can complicate the monitoring of residual disease by analysis of the ratio CD5 + CD19 + /CD19 + . It would be interesting to compare this method with that proposed in the present study.
Finally, Thompson et al 5 hypothesized that mutations or other alterations affecting B29 gene expression or function produce cells with diminished surface BCR that are unresponsive to antigen binding and therefore unable to initiate either growth stimulatory or apoptotic signal cascades. A recent study showed that BCR-signaled apoptosis of B cells required both B29 and mb-1. 19 The B29 gene alterations that result in reduced CD79b and Ig expression may have prognostic significance because normal surface Ig is correlated with poor survival in CLL. 20 In this context, although the follow-up of our patients is still relatively short for a definitive evaluation of the prognostic impact of CD79b expression in CLL, our CD79b + cases had more frequently an advanced clinical stage and an atypical morphology than the CD79b − group.
